CRISPR THERAPEUTICS AG

19 November, 2024

CRISPR Therapeutics Targets Major Expansion with Innovative Gene Therapy Pipeline and Strategic Partnerships Amid Financial Challenges

CRISPR Therapeutics is positioned for significant growth as it aims to expand its pipeline and forge partnerships with organizations like Vertex Pharmaceuticals. The company intends to launch one to t...
Read More

18 November, 2024

CRISPR Therapeutics Launches First Approved CRISPR Treatment Amid Promising Pipeline and Market Challenges

CRISPR Therapeutics is making headlines in the genetic medicine landscape as it pioneers the gene-editing therapy Casgevy, which treats challenging blood disorders. As the first approved CRISPR treatm...
Read More

17 November, 2024

CRISPR Therapeutics Positioned for Growth with Approval of CASGEVY and Expanding Gene Editing Market

CRISPR Therapeutics is making headlines as a major player in the expanding gene editing sector. A recent report forecasts that the global Cas nuclease market will reach $6.56 billion by 2028, with sig...
Read More

16 November, 2024

CRISPR Therapeutics Set to Transform Genetic Medicine with Launch of Casgevy Therapy and Expansion Plans Amidst Market Growth

CRISPR Therapeutics has recently made headlines with the launch of its groundbreaking gene therapy, Casgevy, which is the world's first approved CRISPR-based treatment for sickle cell disease and tran...
Read More